NYSE: CNSCohen & Steers Inc Stock
$63.16-0.88 (-1.37%)
Updated Apr 10, 2026
CNS Price
$63.16
Fair Value Price
N/A
Market Cap
$3.25B
52 Week Low
$58.39
52 Week High
$83.99
P/E
21.12x
P/B
5.78x
P/S
5.78x
PEG
2.95x
Dividend Yield
4.01%
Revenue
$556.12M
Earnings
$153.22M
Gross Margin
86.9%
Operating Margin
36.04%
Profit Margin
27.6%
Debt to Equity
0.43
Operating Cash Flow
-$120M
Beta
1.06
Next Earnings
Apr 16, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CNS Overview
Cohen & Steers, Inc. is an asset management holding company. It takes equity stakes in real estate investment trusts, with holdings in U.S. and international real estate securities. The company also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. Cohen & Steers was founded in 1986 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Asset Management
Industry Rating
D
CNS
Ranked#24 of 78
Ranked#24 of 78
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $285.36 | B | |
| $9.72 | B | |
| $15.84 | B |
Be the first to know about important CNS news, forecast changes, insider trades & much more!
CNS News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNS ($63.16) is trading above its intrinsic value of $24.10, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNS is good value based on its earnings relative to its share price (21.12x), compared to the US market average (29.91x)
P/E vs Market Valuation
CNS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CNS due diligence checks available for Premium users.
Valuation
CNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
21.12x
Industry
29.76x
Market
29.91x
CNS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CNS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.78x
Industry
2.4x
CNS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNS price to earnings growth (PEG)
For valuing profitable companies with growth potential
CNS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
CNS's financial health
Profit margin
Revenue
$143.8M
Net Income
$34.9M
Profit Margin
24.3%
CNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$876.7M
Liabilities
$242.8M
Debt to equity
0.43
CNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.1M
Investing
$39.1M
Financing
$7.6M
CNS vs Asset Management Stocks
Cohen & Steers Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.